Search results for Vibecotamab ELISA Kit
Vibecotamab ELISA Kit, ProteoGenix, KPTX215
Description of Vibecotamab ELISA Kit Introduction Vibecotamab is a promising antibody that has been recently developed as a potential therapeutic target for the treatment of various diseases. This antibody has gained significant attention due to its unique structure and activity, making it a valuable tool for researchers and clinicians. In this article, we will provide a detailed description of Vibecotamab ELISA Kit, highlighting its structure, activity, and potential applications. Structure of Vibecotamab ELISA Kit Vibecotamab is a monoclonal antibody that specifically targets the protein CD3, which is found on the surface of T-cells. The antibody is composed of two heavy chains and two light chains, which are held together by disulfide bonds. The heavy chains consist of a constant region and a variable region, while the light chains contain only a variable region. The variable regions of both the heavy and light chains are responsible for the specificity of the antibody, as they bind to the target protein. Activity of Vibecotamab ELISA Kit Vibecotamab is a highly specific antibody that binds to the CD3 protein on T-cells with high affinity. This binding triggers a cascade of events that ultimately leads to the activation and proliferation of T-cells. The antibody acts as a bridge between T-cells and target cells, such as cancer cells, facilitating the destruction of these cells by the immune system. It also promotes the production of cytokines, which are important signaling molecules that regulate the immune response. Application of Vibecotamab ELISA Kit The unique structure and activity of Vibecotamab make it a valuable tool for various applications in the field of research and clinical practice. Some of the potential applications of Vibecotamab ELISA Kit are listed below: 1. Cancer therapy: Vibecotamab has shown promising results in the treatment of various types of cancer, including leukemia, lymphoma, and solid tumors. The antibody targets cancer cells and activates T-cells, leading to their destruction. It has also been found to enhance the effects of other anti- cancer therapies, making it a potential combination therapy option. 2. Autoimmune diseases: Vibecotamab has also shown potential in the treatment of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. By activating T-cells, the antibody helps in suppressing the overactive immune response that is responsible for these diseases. 3. Immunotherapy: Immunotherapy is a rapidly growing field that focuses on using the body’s immune system to fight diseases. Vibecotamab has the potential to be used as a therapeutic agent in various immunotherapeutic approaches, such as adoptive cell therapy and chimeric antigen receptor (CAR) T-cell therapy. 4. Diagnostic tool: Vibecotamab ELISA Kit can also be used as a diagnostic tool to measure the levels of CD3 protein in the blood. Changes in the levels of this protein can indicate the presence of certain diseases, making it a valuable tool for disease diagnosis and monitoring. Conclusion In conclusion, Vibecotamab ELISA Kit is a highly specific antibody that has shown great potential in the treatment of various diseases. Its unique structure and activity make it a valuable tool for researchers and clinicians, with potential applications in cancer therapy, autoimmune diseases, immunotherapy, and diagnostics. Further research and clinical trials are needed to fully understand the potential of this antibody and its role in improving human health.
Host
Reactivity
Applications
Conjugation
Vibecotamab ELISA Kit, Abbexa, abx395104
This product is currently in development. The lead time for this product may be several months. Please contact us at [email protected] for an updated lead time before purchasing this product. Vibecotamab ELISA Kit is a quantitative ELISA kit for detection of Vibecotamab.Vibecotamab (XmAb®14045) is a tumor-targeted antibody that contains both a CD123 binding domain and a cytotoxic T-cell binding domain (CD3) in a Phase 1 clinical trial for the treatment of acute myeloid leukemia (AML) and other CD123-expressing hematologic malignancies. An XmAb Bispecific Fc domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on vibecotamab. CD123 is highly expressed on AML cells and leukemic stem cells, and it is associated with poorer prognosis in AML patients. Engagement of CD3 by vibecotamab activates T cells for highly potent and targeted killing of CD123-expressing tumor cells.
Host
Reactivity
Human
Applications
ELISA
Conjugation
Please provide the required information below so that we can quickly source your products.